Collaborations & Alliances

Celgene, Dragonfly Enter Strategic TriNKET Platform Pact

Aims to discover and develop Natural Killer Cell-Based Immunotherapies

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Dragonfly Therapeutics, Inc. has entered a global strategic collaboration with Celgene Corp. to discover, develop and commercialize immuno-oncology treatment options for hematological malignancies based on Dragonfly’s Natural Killer (“NK”) cell based TriNKETtechnology platform.    Celgene has the exclusive option to in-license worldwide rights for as many as four therapeutic candidates with potential to treat acute myeloid leukemia, multiple myeloma, and additional hematological malignancies. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters